SynAct Pharma AB (STO: SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
9.20
-0.12 (-1.24%)
Dec 20, 2024, 5:29 PM CET
18.49%
Market Cap 379.72M
Revenue (ttm) n/a
Net Income (ttm) -154.57M
Shares Out 41.30M
EPS (ttm) -4.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 176,444
Open 9.20
Previous Close 9.31
Day's Range 9.05 - 9.31
52-Week Range 4.98 - 13.80
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 18, 2025

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.